A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.
Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources
Study Discovers Overdiagnosis of Progressive Cancer in Routine Clinical Evaluations
A recent retrospective study led by Dr. Marilyn J. Siegel and her team at the Washington University School of Medicine in St. Louis has shed light on…
WUSTL: Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations
In this retrospective study utilizing the mint Lesion™ software[1], researchers found that routine clinical interpretations frequently resulted in the…
Tumor Growth Rate Modeling: A Novel Approach to Evaluating the Efficacy of Cancer Therapies
The 2020 review of Clinical Trial Evidence Supporting US Food and Drug Administrative Approval of Novel Cancer Therapies Between 2000 and 2016…